Jefferies Group's CTMX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 3.07 M shares of CytomX Therapeutics, Inc. (CTMX) worth $14.42 M, representing 0.10% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in CTMX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 3.04 M shares. Largest reduction occurred in Q4 2025, reducing 29,150 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's CytomX Therapeutics (CTMX) Holding Value Over Time
Track share changes against reported price movement
Quarterly CytomX Therapeutics (CTMX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +3.04 M | Add 12809.71% | 3.07 M | $4.70 |
| Q4 2025 | -29,150 | Reduce 55.09% | 23,764 | $4.26 |
| Q3 2025 | +52,914 | New Buy | 52,914 | $3.19 |
Jefferies Group's CytomX Therapeutics Investment FAQs
Jefferies Group first purchased CytomX Therapeutics, Inc. (CTMX) in Q3 2025, acquiring 52,914 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held CytomX Therapeutics, Inc. (CTMX) for 3 quarters since Q3 2025.
Jefferies Group's largest addition to CytomX Therapeutics, Inc. (CTMX) was in Q1 2026, adding 3,067,864 shares worth $14.42 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 3,067,864 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $14.42 M.
As of the Q1 2026 filing, CytomX Therapeutics, Inc. (CTMX) represents approximately 0.10% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in CytomX Therapeutics, Inc. (CTMX) was 3,067,864 shares, as reported at the end of Q1 2026.